# Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

> **NCT05875025** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 20 (actual)

## Conditions studied

- Mucociliary Clearance

## Interventions

- **OTHER:** Placebo formulated with HFA-152a propellant via pMDI
- **OTHER:** Placebo formulated with HFA-134a propellant via pMDI

## Key facts

- **NCT ID:** NCT05875025
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-26
- **Primary completion:** 2023-09-08
- **Final completion:** 2023-09-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875025, "Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05875025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*